Observational studyJournal of clinical oncology : official journal of the American Society of Clinical Oncology2026
Twelve-Month Results From the CISTO Study Comparing Radical Cystectomy Versus Bladder-Sparing Therapy for Recurrent High-Grade Non-Muscle-Invasive Bladder Cancer.
Observational study in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- With Great Cost Comes Great Responsibility: Who Will Own the Rising Costs of Bladder Cancer Care?The Journal of urology · 2026Article
- Gemcitabine-Based Bladder Preservation in BCG-Unresponsive High-Risk NMIBC: Evidence, Limitations, and Clinical Positioning.Biomedicines · 2026Review
- Association of Postoperative Antidepressant and Anxiolytic Exposure With Overall Survival Following Radical Cystectomy for Bladder Cancer.Psycho-oncology · 2026Article
- Meta-analysis of efficacy comparisons between standard- and low-dose Bacillus Calmette-Guerin vaccines in managing non-muscular invasive bladder cancer.Oncology letters · 2026Article
- Systemic induction therapy and the expanding frontier of bladder preservation in MIBC.Nature reviews. Clinical oncology · 2026Article
- Use of Shared Decision-Making in Non-Muscle-Invasive Bladder Cancer: Protocol for a Scoping Review.JMIR research protocols · 2026Article
- Adapting patient priorities care for older adults with non-muscle-invasive bladder cancer: A qualitative inquiry.Urologic oncology · 2026Article
- Long-term outcomes of a cascading salvage strategy for high-risk non-muscle-invasive bladder cancer.BJU international · 2026Article
- Review
- Bidirectional Longitudinal Associations Among Health-Related Quality of Life, Emotional Expressivity, and Readiness to Return to Work in Patients with Non-Muscle-Invasive Bladder Cancer Receiving Intravesical Therapy: A Three-Wave Cohort Study.Patient preference and adherence · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
50 authors.
Funding
Abstract
purposeTo compare patient-reported and clinical outcomes between radical cystectomy (RC) and bladder-sparing therapy (BST) in patients with recurrent high-grade non-muscle-invasive bladder cancer (NMIBC). PATIENTS AND
methodsThis pragmatic, prospective observational cohort study was designed with patients, who selected and prioritized outcomes. Eligible adults were candidates for both RC or BST, had previous induction Bacillus Calmette-Guérin (BCG), and received their last treatment within 12 months. The primary outcome was the EORTC-QLQ-C30 physical function scale at 12 months. Secondary outcomes included other EORTC-QLQ-C30 scales, depression, anxiety, bladder cancer-specific quality of life (QOL), financial burden, and cancer-specific outcomes. Targeted maximum likelihood estimation (TMLE) was used to calculate average treatment effect (ATE) estimates between arms. Inverse probability weighted risk ratios (wRR) were calculated using quasi-Poisson regression.
resultsOf 570 participants (mean age 71.4 years; 21% female), 371 selected BST and 199 selected RC. Physical function was significantly worse in the RC arm at 3 months; by 9 months, there was no difference between arms, and at 12 months, physical function did not differ (ATE, 0.9; 95% CI, -0.6 to 2.4;
conclusionMost patient-prioritized outcomes were similar or better among participants who chose RC compared with BST. These findings support the continued role of RC in managing recurrent high-grade NMIBC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.